|
1
|
Vlachostergios PJ, Puca L and Beltran H:
Emerging Variants of Castration-Resistant Prostate Cancer. Curr
Oncol Rep. 19:322017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Au Yeung SL and Schooling CM: Impact of
glycemic traits, type 2 diabetes and metformin use on breast and
prostate cancer risk: A Mendelian randomization study. BMJ Open
Diabetes Res Care. 7:e0008722019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen CB, Eskin M, Eurich DT, Majumdar SR
and Johnson JA: Metformin, Asian ethnicity and risk of prostate
cancer in type 2 diabetes: A systematic review and meta-analysis.
BMC Cancer. 18:652018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mayer MJ, Klotz LH and Venkateswaran V:
The Effect of Metformin Use during Docetaxel Chemotherapy on
Prostate Cancer Specific and Overall Survival of Diabetic Patients
with Castration Resistant Prostate Cancer. J Urol. 197:1068–1075.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ge R, Wang Z, Wu S, Zhuo Y, Otsetov AG,
Cai C, Zhong W, Wu CL and Olumi AF: Metformin represses cancer
cells via alternate pathways in N-cadherin expressing vs.
N-cadherin deficient cells. Oncotarget. 6:28973–28987. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang Y and Wu XH: Study on the influence
of metformin on castration-resistant prostate cancer PC-3 cell line
biological behavior by its inhibition on PLCε gene-mediated
Notch1/Hes and androgen receptor signaling pathway. Eur Rev Med
Pharmacol Sci. 21:1918–1923. 2017.PubMed/NCBI
|
|
7
|
Abdel-Rahman O: Validation of American
Joint Committee on Cancer eighth staging system among prostate
cancer patients treated with radical prostatectomy. Ther Adv Urol.
10:35–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) μethod. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spiering MJ: The mystery of metformin. J
Biol Chem. 294:6689–6691. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akinyeke T, Matsumura S, Wang X, Wu Y,
Schalfer ED, Saxena A, Yan W, Logan SK and Li X: Metformin targets
c-MYC oncogene to prevent prostate cancer. Carcinogenesis.
34:2823–2832. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sarmento-Cabral A, L-López F, Gahete MD,
Castaño JP and Luque RM: Metformin reduces prostate tumor growth,
in a diet-dependent manner, by modulating multiple signaling
pathways. Mol Cancer Res. 15:862–874. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu D, Hu D, Chen H, Shi G, Fetahu IS, Wu
F, Rabidou K, Fang R, Tan L, Xu S, et al: Glucose-regulated
phosphorylation of TET2 by AMPK reveals a pathway linking diabetes
to cancer. Nature. 559:637–641. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Delma MI: Three May Be Better Than Two: A
Proposal for metformin addition to PI3K/Akt inhibitor-antiandrogen
combination in castration-resistant prostate cancer. Cureus.
10:e34032018.PubMed/NCBI
|
|
14
|
Raffaele M, Pittalà V, Zingales V,
Barbagallo I, Salerno L, Li Volti G, Romeo G, Carota G, Sorrenti V
and Vanella L: Heme oxygenase-1 inhibition sensitizes human
prostate cancer cells towards glucose deprivation and
metformin-mediated cell death. Int J Mol Sci. 20:202019. View Article : Google Scholar
|
|
15
|
Hankinson SJ, Fam M and Patel NN: A review
for clinicians: Prostate cancer and the antineoplastic properties
of metformin. Urol Oncol. 35:21–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ranasinghe WK, Williams S, Ischia J,
Wetherell D, Baldwin G, Shulkes A, Sengupta S, Bolton D and Patel
O: Metformin may offer no protective effect in men undergoing
external beam radiation therapy for prostate cancer. BJU Int. 123
(Suppl 5):36–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lam HM, Nguyen HM, Labrecque MP, Brown LG,
Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT,
et al: Durable Response of enzalutamide-resistant prostate cancer
to supraphysiological testosterone is associated with a
multifaceted growth suppression and impaired DNA damage response
transcriptomic program in patient-derived xenografts. Eur Urol.
77:144–155. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lange T, Oh-Hohenhorst SJ, Joosse SA,
Pantel K, Hahn O, Gosau T, Dyshlovoy SA, Wellbrock J, Feldhaus S,
Maar H, et al: Development and characterization of a spontaneously
metastatic patient-derived xenograft model of human prostate
cancer. Sci Rep. 8:175352018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Y, Zeng X, Tang H, Ye D and Liu J:
Combination of metformin and paclitaxel suppresses proliferation
and induces apoptosis of human prostate cancer cells via oxidative
stress and targeting the mitochondria-dependent pathway. Oncol
Lett. 17:4277–4284. 2019.PubMed/NCBI
|
|
20
|
Sun W, Li L, Du Z, Quan Z, Yuan M, Cheng
H, Gao Y, Luo C and Wu X: Combination of phospholipase Cε knockdown
with GANT61 sensitizes castration resistant prostate cancer cells
to enzalutamide by suppressing the androgen receptor signaling
pathway. Oncol Rep. 41:2689–2702. 2019.PubMed/NCBI
|
|
21
|
Rice MA, Hsu EC, Aslan M, Ghoochani A, Su
A and Stoyanova T: Loss of Notch1 activity inhibits prostate cancer
growth and metastasis and sensitizes prostate cancer cells to
antiandrogen therapies. Mol Cancer Ther. 18:1230–1242. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Whitburn J, Edwards CM and Sooriakumaran
P: Metformin and Prostate cancer: A new role for an old drug. Curr
Urol Rep. 18:462017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zingales V, Distefano A, Raffaele M,
Zanghi A, Barbagallo I and Vanella L: Metformin: A bridge between
diabetes and prostate cancer. Front Oncol. 7:2432017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong Y, Lee S and Won S: The preventive
effect of metformin on progression of benign prostate hyperplasia:
A nationwide population-based cohort study in Korea. PLoS One.
14:e02193942019. View Article : Google Scholar : PubMed/NCBI
|
